Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

Treatment Intensification Based on Disease Activity Parameters or on Cartilage Breakdown Markers in Early Rheumatoid Arthritis.

- candidate number0
- NTR NumberNTR80
- Date ISRCTN created12-sep-2005
- date ISRCTN requested15-aug-2005
- Date Registered NTR13-mei-2005
- Secondary IDsP03627 
- Public TitleTreatment Intensification Based on Disease Activity Parameters or on Cartilage Breakdown Markers in Early Rheumatoid Arthritis.
- Scientific TitleTreatment Intensification Based on Disease Activity Parameters or on Cartilage Breakdown Markers in Early Rheumatoid Arthritis.
- hypothesisIn early RA, does treatment intensification (by conventional and biological means) aimed at keeping urine CTX-2 levels below 150 nmol/µmol creatinine lead to a lower radiological progression than treatment intensification aimed at keeping DAS28 at or below 3.2?
- Healt Condition(s) or Problem(s) studiedRheumatoid arthritis
- Inclusion criteriaPatients must have:
1. Rheumatoid arthritis (ACR criteria met cumulatively);
2. Requiring treatment: DAS28 >3.2;
3. Propensity for radiographic progression: urinary CTX-2 > 150 ng/µmol creatinine.
- Exclusion criteria1. Unwillingness to participate in the study and comply with its procedures by signing a written informed consent;

More chance of harm
2. Contraindication to study drugs
a. Previous serious adverse reaction or documented allergy to any of the trial drugs or their constituents;
b. Previous inability to tolerate sulphasalazine (minimum 1g/d), hydroxychloroquine (minimum 200mg/d) methotrexate (minimum 7.5mg/week) or oral prednisolone;
3. Active infection or those at high risk of infection;
a. Abnormal chest X-ray or positive tuberculin test suggestive of previous TB that has not been adequately treated;
b. Chronic leg ulcers;
c. Septic arthritis of a native joint within the last 12 months;
d. Previous prosthetic joint sepsis within the last 12 months, indefinitely if prosthesis remains in situ;
e. Bronchiectasis, indwelling urinary catheter and other situation deemed high risk by treating physician;
4. Malignancy, excluding basal cell carcinoma and malignancies diagnosed and treated more than 10 years previously, in whom there is a high probability of cure in the opinion of the treating physician;
5. Pregnancy, planned pregnancy or lactation. Women of childbearing age (includes women who are less than 1 year postmenopausal and women who become sexually active) must be using an acceptable method of birth control (e.g., hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or be surgically sterilized (e.g., hysterectomy or tubal ligation);
6. Current signs or symptoms of severe, progressive, or uncontrolled renal, haematological, hepatic, respiratory, gastrointestinal, endocrine, cardiac, neurological or cerebral disease. Specifically, this includes cardiac failure (NYHA class 3 or 4);
7. Screening blood tests at baseline which show haemoglobin < 8g/l, total WBC < 3.5 or neutrophils < 1.5, platelets < 100. Patients will also be excluded if serum ALT or alkaline phosphatase are more than twice the upper limit of normal, or impaired renal function: creatinine > 100 mumol/L AND Cockroft creatinine clearance < 40 ml/min;
8. Subjects who have used any investigational product within 30 days prior to enrollment;
9. Age < 18;

Less chance of benefit
10. Disease duration > 36 months (date of diagnosis by rheumatologist);
11. Previous treatment of RA with more than two DMARDs. Systemic glucocorticoids are counted as DMARDs. Treatment is defined as a cumulative period of 8 weeks or more;

Measurement difficulties
12. Insufficient command of local language;
13. Illiteracy;
14. Inability to comply with the protocol (opinion of treating physician).
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingDouble
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-okt-2003
- planned closingdate30-sep-2005
- Target number of participants40
- InterventionsThe study design randomizes to two monitoring strategies that lead to subsequent steps in the treatment schedule: either clinical monitoring by Disease Activity Score (DAS28) to achieve and keep the DAS below 2.6 (clinical remission); or: Lab monitoring by CTX-2 to achieve and keep the urinary level of CTX-2 below 150 ng/µmol creatinine. All patients will receive ‘traditional’ combination DMARD therapy (Disease-Monifying Antirheumatic Therapy) for a minimum of 22 weeks: step 1 is evaluated at week 8, and step 2 at week 22.

Patients will receive treatment intensification according to achieved levels of DAS28 (DAS group) or according to achieved levels of CTX-2 (CTX group).
- Primary outcome1. DAS: Disease activity score (28 joints) calculated from swollen and tender joint counts, ESR, patient global assessment of disease activity (10 cm VAS);
2. CTX-2: measured in spot urine (delivered 1 week before visit) together with creatinine (method Garnero, Lyon).
- Secondary outcome1. WHO/ILAR core set; DAS remission, EULAR improvement; ACR remission, ACR20,etc; EuroQoL;
2. Efficacy Self assessment: RADAI joint score, fatigue VAS;
3. Bone Mass: DEXA lumbar spine; Right hip (neck).
- TimepointsN/A
- Trial web siteN/A
- statusstopped: trial finished
- Sponsor/Initiator VU University Medical Center, Departments of Clinical Epidemiology and Biostatistics and Rheumatology.
- Funding
(Source(s) of Monetary or Material Support)
VU University Medical Center, Schering-Plough
- PublicationsN/A
- Brief summaryN/A
- Main changes (audit trail)
- RECORD11-aug-2005 - 11-sep-2008

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar
  • Dit zijn de gegevens waarmee uw trial is aangemeld en geregistreerd in het Nederlands Trial Register